Emmanuel Kutu

Mr. Emmanuel Kutu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
EKEmmanuel Kutu
Emmanuel Kutu
DMDerrick Adu Mensah
Derrick Adu Mensah
VOVera Serwaa Opoku
Vera Serwaa Opoku
JBJohn Boateng
John Boateng
JOJohn Opoku
John Opoku
Alexander Yaw DebrahAlexander Yaw Debrah
Alexander Yaw Debrah
Background: The lack of a short-course of safe and effective macrofilaricidal therapy for lymphatic filariasis (LF) hinders elimination efforts, especially in the endgame scenario. Preclinical studies in mice demonstrated that high-dose rifampicin (RIF) plus albendazole (ALB) produced macrofilaricidal effects within seven days, prompting this randomised, open-label, parallel-group, interventional phase II pilot trial to determine the efficacy of high-dose RIF plus ALB against LF in humans. Methods: In three LF-endemic districts of Ghana’s Upper East Region, circulating filarial antigen (CFA)-positive individuals aged 18 to 55 years identified using the Alere Filariasis Test Strip were enrolled into the study. The participants were randomised through a centralized computer-generated randomisation into four treatment arms. They were treated according to the arm they were assigned to and followed up at 4-, 6-, 12-, and 18-months post-treatment to monitor changes in CFA status and levels, as well as adverse events. Outcome assessors were blinded to minimize assessment bias. Results: A total of 69 eligible participants were randomised into four treatment arms: RIF (35 mg/kg/day) + ALB (400 mg/day) for 7 days (n = 17), RIF (35 mg/kg/day) + ALB (400 mg/day) for 14 days (n = 18), ALB alone for 14 days (n = 17), and an untreated controlled group participating in standard mass drug administration (n = 17). All regimens were well tolerated, with no serious adverse events. Even though CFA positivity declined across all groups, with maximal reductions at 18 months, the RIF + ALB 7-day regimen consistently showed the highest decline, while ALB alone was the least effective. RIF + ALB groups exhibited early antigen decline by 4 months, unlike comparator groups, where reductions occurred from 12 months. Conclusions: These findings suggest macrofilaricidal activity of high-dose RIF plus ALB, supporting further trials in larger, microfilaraemic populations. The trial was registered in the Pan African Clinical Trials Registry on 9 September 2020 under the code PACTR202009704006025.Funding was by the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2), with grant code TMA2018SF-2451-ASTAWOL, and by the German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung-BMBF) under agreement with Gesellschaft für Internationale Zusammenarbeit (GIZ) through agreement number: 81204851.

23 January 2026 in Journal of Science and Technology (Ghana)
Verified
Journal Article
Open access
DMDerrick Adu Mensah
Derrick Adu Mensah
LDLinda B. Debrah
Linda B. Debrah
JBJohn Boateng
John Boateng
MAMonica Ahiadorme
Monica Ahiadorme
JOJubin Kwaku Osei-Mensah
Jubin Kwaku Osei-Mensah
Alexander Yaw DebrahAlexander Yaw Debrah
Alexander Yaw Debrah
Introduction Onchocerciasis, a neglected tropical disease caused by Onchocerca volvulus, remains a significant public health concern in endemic regions despite decades of mass drug administration (MDA) with ivermectin (IVM). This study evaluates the impact of IVM MDA on onchocerciasis transmission in the Sefwi Akontombra district of Ghana and identifies factors contributing to the persistence of the infection. Methodology A cross-sectional study was conducted across 25 communities in the district. Participants were clinically examined for palpable onchocercomata, and compliance with IVM treatment was assessed through structured interviews and community health records. Participants with one or more palpable sub-cutaneous nodule had skin snips taken from the iliac crests for microfilariae assessment. Data were analysed using descriptive statistics, chi-square tests, and logistic regression models. Results Of the 1,980 participants assessed, 35.4% had subcutaneous nodules, with variations in prevalence across communities. The district community microfilariae load (CMFL) and geometric mean intensity were 0.25 MF/ss and 0.26 MF/ss respectively. Age, MDA compliance and gender were the independent predictive factors significantly associated with onchocerciasis in the district. Conclusion While MDA has reduced onchocerciasis prevalence, transmission persists. To accelerate elimination efforts, targeted interventions should focus on increasing MDA compliance through intensified community engagement, integrating alternative treatment strategies such as anti-Wolbachia therapy, and adopting more sensitive diagnostic tools for improved surveillance.